Robert Stratta to Survival Analysis
This is a "connection" page, showing publications Robert Stratta has written about Survival Analysis.
Connection Strength
0.758
-
Rogers J, Farney AC, Orlando G, Harriman D, Reeves-Daniel A, Jay CL, Doares W, Kaczmorski S, Gautreaux MD, Stratta RJ. Dual Kidney Transplantation from Donors at the Extremes of Age. J Am Coll Surg. 2019 04; 228(4):690-705.
Score: 0.148
-
Singh RP, Farney AC, Rogers J, Ashcraft E, Hart L, Doares W, Hartmann EL, Reeves-Daniel A, Adams PL, Stratta RJ. Analysis of bacteremia after pancreatic transplantation with enteric drainage. Transplant Proc. 2008 Mar; 40(2):506-9.
Score: 0.070
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transplant Proc. 2005 Oct; 37(8):3531-4.
Score: 0.059
-
Stratta RJ, Sundberg AK, Farney AC, Rohr MS, Hartmann EL, Adams PL. Experience with alternate-day thymoglobulin induction in pancreas transplantation with portal-enteric drainage. Transplant Proc. 2005 Oct; 37(8):3546-8.
Score: 0.059
-
Stratta RJ, Thacker LR, Sundberg AK. Multivariate analysis of the influence of donor and recipient cytomegalovirus sero-pairing on outcomes in simultaneous kidney-pancreas transplantation: the South-Eastern Organ Procurement Foundation Experience. Transplant Proc. 2005 Mar; 37(2):1271-3.
Score: 0.057
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. Does surgical technique influence outcomes after simultaneous kidney-pancreas transplantation? Transplant Proc. 2004 May; 36(4):1076-7.
Score: 0.054
-
Stratta RJ, Alloway RR, Lo A, Hodge EE. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients. Transplant Proc. 2004 May; 36(4):1082-3.
Score: 0.054
-
Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation. 2003 Apr 27; 75(8):1260-6.
Score: 0.050
-
Sudan D, Sudan R, Stratta R. Long-term outcome of simultaneous kidney-pancreas transplantation: analysis of 61 patients with more than 5 years follow-up. Transplantation. 2000 Feb 27; 69(4):550-5.
Score: 0.040
-
Stratta RJ. Analysis of mortality after pancreas transplantation. Transplant Proc. 1998 Mar; 30(2):283.
Score: 0.035
-
Stratta RJ, Taylor RJ, Zorn BH, Ozaki C, Larsen JL, Langnas AN, Wood RP, Duckworth WC, Wahl TO, Gallagher TF, et al. Combined pancreas--kidney transplantation in Nebraska. Nebr Med J. 1991 Dec; 76(12):385-91.
Score: 0.023
-
Rogers J, Stratta RJ, Lo A, Alloway RR. Inferior late functional and metabolic outcomes in African American simultaneous kidney-pancreas recipients. Transplant Proc. 2005 Oct; 37(8):3552-4.
Score: 0.015
-
Reddy KS, Stratta RJ, Alloway RR, Lo A, Hodge EE. The impact of delayed graft function of the kidney on the pancreas allograft in simultaneous kidney-pancreas transplantation. Transplant Proc. 2004 May; 36(4):1078-9.
Score: 0.013
-
Reddy KS, Stablein D, Taranto S, Stratta RJ, Johnston TD, Waid TH, McKeown JW, Lucas BA, Ranjan D. Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. Am J Kidney Dis. 2003 Feb; 41(2):464-70.
Score: 0.012
-
Lo A, Stratta RJ, Hathaway DK, Egidi MF, Shokouh-Amiri MH, Grewal HP, Winsett R, Trofe J, Alloway RR, Gaber AO. Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric versus systemic-bladder drainage. Am J Kidney Dis. 2001 Jul; 38(1):132-43.
Score: 0.011
-
Lo A, Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Kisilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis. Transpl Infect Dis. 2001 Mar; 3(1):8-15.
Score: 0.011
-
Reddy KS, Stratta RJ, Shokouh-Amiri H, Alloway R, Somerville T, Egidi MF, Gaber LW, Gaber AO. Simultaneous kidney-pancreas transplantation without antilymphocyte induction. Transplantation. 2000 Jan 15; 69(1):49-54.
Score: 0.010
-
Gruessner RW, Burke GW, Stratta R, Sollinger H, Benedetti E, Marsh C, Stock P, Boudreaux JP, Martin M, Drangstveit MB, Sutherland DE, Gruessner A. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation. 1996 Jan 27; 61(2):261-73.
Score: 0.008
-
Trail KC, Stratta RJ, Larsen JL, Ruby EI, Patil KD, Langnas AN, Donovan JP, Sorrell MF, Zetterman RK, Pillen TJ, et al. Results of liver transplantation in diabetic recipients. Surgery. 1993 Oct; 114(4):650-6; discussion 656-8.
Score: 0.006
-
Langnas AN, Inagaki M, Bynon JS, Ozaki CF, Stratta RJ, Shaw BW. Hepatic retransplantation in children. Transplant Proc. 1993 Apr; 25(2):1921-2.
Score: 0.006
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):641-3.
Score: 0.006
-
Klintmalm GB, Goldstein R, Gonwa T, Wiesner RH, Krom RA, Shaw BW, Stratta R, Ascher NL, Roberts JW, Lake J, et al. Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. Transplant Proc. 1993 Feb; 25(1 Pt 1):679-88.
Score: 0.006
-
Castaldo P, Stratta RJ, Wood RP, Markin RS, Patil KD, Shaefer MS, Langnas AN, Reed EC, Li S, Pillen TJ, et al. Fungal disease in liver transplant recipients: a multivariate analysis of risk factors. Transplant Proc. 1991 Feb; 23(1 Pt 2):1517-9.
Score: 0.005